Table of Contents Author Guidelines Submit a Manuscript
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

Disease Markers
Volume 2016, Article ID 9214056, 14 pages
http://dx.doi.org/10.1155/2016/9214056
Review Article

Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications

1Medical Oncology Department, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain
2Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Mardid, Spain

Received 31 March 2016; Revised 8 June 2016; Accepted 9 June 2016

Academic Editor: Monica Neagu

Copyright © 2016 A. Quintanal-Villalonga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1, pp. 7–30, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. R. S. Herbst, J. V. Heymach, and S. M. Lippman, “Lung cancer,” The New England Journal of Medicine, vol. 359, no. 13, pp. 1367–1380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. B. J. Flehinger, M. Kimmel, and M. R. Melamed, “The effect of surgical treatment on survival from early lung cancer. Implications for screening,” Chest, vol. 101, no. 4, pp. 1013–1018, 1992. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Imielinski, A. H. Berger, P. S. Hammerman et al., “Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing,” Cell, vol. 150, no. 6, pp. 1107–1120, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. The Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of gastric adenocarcinoma,” Nature, vol. 513, no. 7517, pp. 202–209, 2014. View at Publisher · View at Google Scholar
  7. L. Ding, G. Getz, D. A. Wheeler et al., “Somatic mutations affect key pathways in lung adenocarcinoma,” Nature, vol. 455, no. 7216, pp. 1069–1075, 2008. View at Google Scholar
  8. The Cancer Genome Atlas Research Network, “Comprehensive genomic characterization of squamous cell lung cancers,” Nature, vol. 489, no. 7417, pp. 519–525, 2012. View at Publisher · View at Google Scholar
  9. M. Peifer, L. Fernández-Cuesta, M. L. Sos et al., “Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer,” Nature Genetics, vol. 44, no. 10, pp. 1104–1110, 2012. View at Publisher · View at Google Scholar
  10. C. M. Rudin, S. Durinck, E. W. Stawiski et al., “Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer,” Nature Genetics, vol. 44, no. 10, pp. 1111–1116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. George, J. S. Lim, S. J. Jang et al., “Comprehensive genomic profiles of small cell lung cancer,” Nature, vol. 524, no. 7563, pp. 47–53, 2015. View at Google Scholar
  12. S. R. Hubbard, “Structural analysis of receptor tyrosine kinases,” Progress in Biophysics and Molecular Biology, vol. 71, no. 3-4, pp. 343–358, 1999. View at Google Scholar
  13. A. Ullrich and J. Schlessinger, “Signal transduction by receptors with tyrosine kinase activity,” Cell, vol. 61, no. 2, pp. 203–212, 1990. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Margolis, S. G. Rhee, S. Felder et al., “EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling,” Cell, vol. 57, no. 7, pp. 1101–1107, 1989. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Blume-Jensen and T. Hunter, “Oncogenic kinase signalling,” Nature, vol. 411, no. 6835, pp. 355–365, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Sorkin and L. K. Goh, “Endocytosis and intracellular trafficking of ErbBs,” Experimental Cell Research, vol. 315, no. 4, pp. 683–696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Monsonego-Ornan, R. Adar, T. Feferman, O. Segev, and A. Yayon, “The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation,” Molecular and Cellular Biology, vol. 20, no. 2, pp. 516–522, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Gupta, A. M. Dastane, R. McKenna Jr., and A. M. Marchevsky, “The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current ‘best evidence’ with meta-analysis,” Human Pathology, vol. 40, no. 3, pp. 356–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. R. T. Dungo and G. M. Keating, “Afatinib: first global approval,” Drugs, vol. 73, no. 13, pp. 1503–1515, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Mitsudomi and Y. Yatabe, “Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer,” FEBS Journal, vol. 277, no. 2, pp. 301–308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. C. J. Langer, “Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer?” Journal of Clinical Oncology, vol. 31, no. 27, pp. 3303–3306, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. T. M. Brand, M. Iida, C. Li, and D. L. Wheeler, “The nuclear epidermal growth factor receptor signaling network and its role in cancer,” Discovery Medicine, vol. 12, no. 66, pp. 419–432, 2011. View at Google Scholar · View at Scopus
  25. S.-C. Wang, Y. Nakajima, Y.-L. Yu et al., “Tyrosine phosphorylation controls PCNA function through protein stability,” Nature Cell Biology, vol. 8, no. 12, pp. 1359–1368, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Dittmann, C. Mayer, R. Kehlbach, and H. P. Rodemann, “Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK,” Molecular Cancer, vol. 7, article 69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Liccardi, J. A. Hartley, and D. Hochhauser, “EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment,” Cancer Research, vol. 71, no. 3, pp. 1103–1114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. H. Kimura, M. Suminoe, K. Kasahara et al., “Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA),” British Journal of Cancer, vol. 97, no. 6, pp. 778–784, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. T. K. F. Yung, K. C. A. Chan, T. S. K. Mok, J. Tong, K.-F. To, and Y. M. D. Lo, “Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients,” Clinical Cancer Research, vol. 15, no. 6, pp. 2076–2084, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Mok, Y.-L. Wu, J. S. Lee et al., “Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy,” Clinical Cancer Research, vol. 21, no. 14, pp. 3196–3203, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Zheng, X. Ye, M. Z. Zhang et al., “Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance,” Scientific Reports, vol. 2016, Article ID 20913, 6 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Kawahara, C. Fukumitsu, T. Taira et al., “Epidermal growth factor receptor mutation status in cell-free DNA supernatant of bronchial washings and brushings,” Cancer Cytopathology, vol. 123, no. 10, pp. 620–628, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson et al., “Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4247–4253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. J. Cui, “Targeting receptor tyrosine kinase MET in cancer: Small molecule inhibitors and clinical progress,” Journal of Medicinal Chemistry, vol. 57, no. 11, pp. 4427–4453, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Drilon, N. Rekhtman, M. Ladanyi, and P. Paik, “Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy,” The Lancet Oncology, vol. 13, no. 10, pp. e418–e426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Bean, C. Brennan, J.-Y. Shih et al., “MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20932–20937, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. X. Wang, N. Song, Y. Zhang et al., “Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer,” Tumor Biology, vol. 36, no. 9, pp. 7053–7059, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. M. W. Wynes, T. K. Hinz, D. Gao et al., “FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies,” Clinical Cancer Research, vol. 20, no. 12, pp. 3299–3309, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Egeblad, M. G. Rasch, and V. M. Weaver, “Dynamic interplay between the collagen scaffold and tumor evolution,” Current Opinion in Cell Biology, vol. 22, no. 5, pp. 697–706, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Pitini, C. Arrigo, C. Di Mirto, P. Mondello, and G. Altavilla, “Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia,” Lung Cancer, vol. 82, no. 1, pp. 171–172, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. T. Erler, K. L. Bennewith, T. R. Cox et al., “Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche,” Cancer Cell, vol. 15, no. 1, pp. 35–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Baserga, A. Hongo, M. Rubini, M. Prisco, and B. Valentinis, “The IGF-I receptor in cell growth, transformation and apoptosis,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1332, no. 3, pp. F105–F126, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., “MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp. 1039–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. G. R. Oxnard, “Strategies for overcoming acquired resistance to epidermal growth factor receptor-targeted therapies in lung cancer,” Archives of Pathology and Laboratory Medicine, vol. 136, no. 10, pp. 1205–1209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. L. V. Sequist, B. A. Waltman, D. Dias-Santagata et al., “Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors,” Science Translational Medicine, vol. 3, no. 75, Article ID 75ra26, 2011. View at Publisher · View at Google Scholar
  46. D. LeRoith, H. Werner, D. Beitner-Johnson, and C. T. Roberts Jr., “Molecular and cellular aspects of the insulin-like growth factor I receptor,” Endocrine Reviews, vol. 16, no. 2, pp. 143–163, 1995. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Gualberto, M. Dolled-Filhart, M. Gustavson et al., “Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition,” Clinical Cancer Research, vol. 16, no. 18, pp. 4654–4665, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. T. Agulló-Ortuño, C. V. Díaz-García, A. Agudo-López et al., “Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer,” Journal of Cancer Research and Clinical Oncology, vol. 141, no. 1, pp. 43–53, 2015. View at Publisher · View at Google Scholar
  49. T. Takahashi, M. Sonobe, M. Kobayashi et al., “Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene,” Annals of Surgical Oncology, vol. 17, no. 3, pp. 889–897, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Shimamura, H. Ji, Y. Minami et al., “Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272,” Cancer Research, vol. 66, no. 13, pp. 6487–6491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. V. H. Veldore, S. Patil, C. Satheesh et al., “Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: an effort to explore new drug targets,” Indian Journal of Cancer, vol. 52, no. 2, pp. 243–248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. J. S. Park, J.-S. Lee, E. Y. Kim et al., “The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer,” Lung Cancer, vol. 88, no. 3, pp. 325–331, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Casaluce, A. Sgambato, P. Maione et al., “ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC,” Targeted Oncology, vol. 8, no. 1, pp. 55–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Sasaki, S. J. Rodig, L. R. Chirieac, and P. A. Jänne, “The biology and treatment of EML4-ALK non-small cell lung cancer,” European Journal of Cancer, vol. 46, no. 10, pp. 1773–1780, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Soda, Y. L. Choi, M. Enomoto et al., “Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer,” Nature, vol. 448, no. 7153, pp. 561–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Gridelli, F. De Marinis, F. Cappuzzo et al., “Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology,” Clinical Lung Cancer, vol. 15, no. 3, pp. 173–181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Gridelli, S. Peters, A. Sgambato, F. Casaluce, A. A. Adjei, and F. Ciardiello, “ALK inhibitors in the treatment of advanced NSCLC,” Cancer Treatment Reviews, vol. 40, no. 2, pp. 300–306, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. E. L. Kwak, Y. J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010. View at Google Scholar
  59. B. J. Solomon, T. Mok, D.-W. Kim et al., “First-line crizotinib versus chemotherapy in ALK-positive lung cancer,” The New England Journal of Medicine, vol. 371, no. 23, pp. 2167–2177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Ambrogio, G. Gómez-López, M. Falcone et al., “Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma,” Nature Medicine, vol. 22, no. 3, pp. 270–277, 2016. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Rikova, A. Guo, Q. Zeng et al., “Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer,” Cell, vol. 131, no. 6, pp. 1190–1203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. U. McDermott, A. J. Iafrate, N. S. Gray et al., “Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors,” Cancer Research, vol. 68, no. 9, pp. 3389–3395, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Bergethon, A. T. Shaw, S.-H. I. Ou et al., “ROS1 rearrangements define a unique molecular class of lung cancers,” Journal of Clinical Oncology, vol. 30, no. 8, pp. 863–870, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. S. Ju, W.-C. Lee, J.-Y. Shin et al., “A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing,” Genome Research, vol. 22, no. 3, pp. 436–445, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Lipson, M. Capelletti, R. Yelensky et al., “Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies,” Nature Medicine, vol. 18, no. 3, pp. 382–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Kohno, H. Ichikawa, Y. Totoki et al., “KIF5B-RET fusions in lung adenocarcinoma,” Nature Medicine, vol. 18, no. 3, pp. 375–377, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Vaishnavi, M. Capelletti, A. T. Le et al., “Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer,” Nature Medicine, vol. 19, no. 11, pp. 1469–1472, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. W. Pao and N. Girard, “New driver mutations in non-small-cell lung cancer,” The Lancet Oncology, vol. 12, no. 2, pp. 175–180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Stephens, C. Hunter, G. Bignell et al., “Lung cancer: intragenic ERBB2 kinase mutations in tumours,” Nature, vol. 431, no. 7008, pp. 525–526, 2004. View at Publisher · View at Google Scholar
  70. M. E. Arcila, J. E. Chaft, K. Nafa et al., “Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas,” Clinical Cancer Research, vol. 18, no. 18, pp. 4910–4918, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Mazieres, S. Peters, B. Lepage et al., “Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives,” Journal of Clinical Oncology, vol. 31, no. 16, pp. 1997–2003, 2013. View at Publisher · View at Google Scholar
  72. D. Li, L. Ambrogio, T. Shimamura et al., “BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models,” Oncogene, vol. 27, no. 34, pp. 4702–4711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Weiss, M. L. Sos, D. Seidel et al., “Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer,” Science Translational Medicine, vol. 2, no. 62, Article ID 62ra93, 2010. View at Publisher · View at Google Scholar
  74. A. Dutt, A. H. Ramos, P. S. Hammerman et al., “Inhibitor-sensitive fgfr1 amplification in human non-small cell lung cancer,” PLoS ONE, vol. 6, no. 6, Article ID e20351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. A. J. Bass, H. Watanabe, C. H. Mermel et al., “SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas,” Nature Genetics, vol. 41, no. 11, pp. 1238–1242, 2009. View at Publisher · View at Google Scholar
  76. H. Kotani, H. Ebi, H. Kitai et al., “Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression,” Oncogene, vol. 35, no. 27, pp. 3587–3597, 2016. View at Publisher · View at Google Scholar
  77. J. H. Tchaicha, E. A. Akbay, A. Altabef et al., “Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC,” Cancer Research, vol. 74, no. 17, pp. 4676–4684, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. P. S. Hammerman, M. L. Sos, A. H. Ramos et al., “Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer,” Cancer Discovery, vol. 1, no. 1, pp. 78–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. T. Shaw and B. Solomon, “Targeting anaplastic lymphoma kinase in lung cancer,” Clinical Cancer Research, vol. 17, no. 8, pp. 2081–2086, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. S.-J. An, Z.-H. Chen, J. Su et al., “Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status,” PLoS ONE, vol. 7, no. 6, Article ID e40109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Day, B. Waters, K. Spiegel et al., “Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib,” European Journal of Pharmacology, vol. 599, no. 1–3, pp. 44–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. J. Wall, E. Werner, Z. Werb, and Y. A. DeClerck, “Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen,” The Journal of Biological Chemistry, vol. 280, no. 48, pp. 40187–40194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. K. B. Hotary, E. D. Allen, P. C. Brooks, N. S. Datta, M. W. Long, and S. J. Weiss, “Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix,” Cell, vol. 114, no. 1, pp. 33–45, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Sasaki, M. Shitara, K. Yokota et al., “DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients,” Oncology Letters, vol. 4, no. 1, pp. 33–37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Östman, “PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma,” Cytokine & Growth Factor Reviews, vol. 15, no. 4, pp. 275–286, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. A. H. Ramos, A. Dutt, C. Mermel et al., “Amplification of chromosomal segment 4q12 in non-small cell lung cancer,” Cancer Biology and Therapy, vol. 8, no. 21, pp. 2042–2050, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. W. B. Fang, D. M. Brantley-Sieders, M. A. Parker, A. D. Reith, and J. Chen, “A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis,” Oncogene, vol. 24, no. 53, pp. 7859–7868, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. A. B. Larsen, M. W. Pedersen, M.-T. Stockhausen, M. V. Grandal, B. Van Deurs, and H. S. Poulsen, “Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility,” Molecular Cancer Research, vol. 5, no. 3, pp. 283–293, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. L. Faoro, P. A. Singleton, G. M. Cervantes et al., “EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation,” The Journal of Biological Chemistry, vol. 285, no. 24, pp. 18575–18585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. A. J. Wong, J. M. Ruppert, S. H. Bigner et al., “Structural alterations of the epidermal growth factor receptor gene in human gliomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 2965–2969, 1992. View at Google Scholar
  91. H. Ji, X. Zhao, Y. Yuza et al., “Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 20, pp. 7817–7822, 2006. View at Publisher · View at Google Scholar
  92. H. Sasaki, O. Kawano, K. Endo, H. Yukiue, M. Yano, and Y. Fujii, “EGFRvIII mutation in lung cancer correlates with increased EGFR copy number,” Oncology Reports, vol. 17, no. 2, pp. 319–323, 2007. View at Google Scholar · View at Scopus
  93. J. S. Ross, K. Wang, O. R. Elkadi et al., “Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer,” Journal of Clinical Pathology, vol. 67, no. 9, pp. 772–776, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. A. M. Schultheis, M. Bos, K. Schmitz et al., “Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer,” Modern Pathology, vol. 27, no. 2, pp. 214–221, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. F. Yang, Y. Gao, J. Geng et al., “Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer,” International Journal of Clinical and Experimental Pathology, vol. 6, no. 12, pp. 2846–2854, 2013. View at Google Scholar · View at Scopus
  96. A. Thomas, J.-H. Lee, Z. Abdullaev et al., “Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer,” Journal of Thoracic Oncology, vol. 9, no. 4, pp. 567–571, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. O. E. Pardo, J. Latigo, R. E. Jeffery et al., “The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo,” Cancer Research, vol. 69, no. 22, pp. 8645–8651, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. B. Fischer, M. Marinov, and A. Arcaro, “Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?” Cancer Treatment Reviews, vol. 33, no. 4, pp. 391–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Sattler and R. Salgia, “Molecular and cellular biology of small cell lung cancer,” Seminars in Oncology, vol. 30, no. 1, pp. 57–71, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. Cancer Genome Atlas Research Network, “Comprehensive molecular profiling of lung adenocarcinoma,” Nature, vol. 511, no. 7511, pp. 543–550, 2014. View at Google Scholar
  101. H. Go, Y. K. Jeon, H. J. Park, S.-W. Sung, J.-W. Seo, and D. H. Chung, “High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 5, no. 3, pp. 305–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, and T. Mitsudomi, “Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers,” Journal of Thoracic Oncology, vol. 4, no. 1, pp. 5–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. V. Woude, “Targeting MET in cancer: rationale and progress,” Nature Reviews Cancer, vol. 12, no. 2, pp. 89–103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. D. R. Spigel, T. J. Ervin, R. A. Ramlau et al., “Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 31, no. 32, pp. 4105–4114, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Yoshioka, K. Azuma, N. Yamamoto et al., “A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study),” Annals of Oncology, vol. 26, no. 10, Article ID mdv288, pp. 2066–2072, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. J. J. Sacco and M. J. Clague, “Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance,” Translational Lung Cancer Research, vol. 4, no. 3, pp. 242–252, 2015. View at Google Scholar
  107. W. Zheng, Y.-J. Xu, S.-F. Qiu et al., “Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 10, pp. 4393–4399, 2015. View at Publisher · View at Google Scholar · View at Scopus
  108. G. Bellezza, R. Del Sordo, R. Colella et al., “Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC),” Virchows Archiv, vol. 463, no. 5, pp. 663–671, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. F. Cappuzzo, P. A. Jänne, M. Skokan et al., “MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients,” Annals of Oncology, vol. 20, no. 2, pp. 298–304, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. H. Yasuda, S. Kobayashi, and D. B. Costa, “EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications,” The Lancet Oncology, vol. 13, no. 1, pp. e23–e31, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Suda, H. Mizuuchi, Y. Maehara, and T. Mitsudomi, “Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny,” Cancer and Metastasis Reviews, vol. 31, no. 3-4, pp. 807–814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. M. G. Oser, M. J. Niederst, L. V. Sequist, and J. A. Engelman, “Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin,” The Lancet Oncology, vol. 16, no. 4, pp. e165–e172, 2015. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Kobayashi, T. J. Boggon, T. Dayaram et al., “EGFR mutation and resistance of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 352, no. 8, pp. 786–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. W. Pao, V. A. Miller, K. A. Politi et al., “Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Medicine, vol. 2, no. 3, article e73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. R. Rosell, M. A. Molina, C. Costa et al., “Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations,” Clinical Cancer Research, vol. 17, no. 5, pp. 1160–1168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. J. F. Gainor and A. T. Shaw, “Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3987–3996, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. E. L. Kwak, R. Sordella, D. W. Bell et al., “Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 21, pp. 7665–7670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. L. V. Sequist, B. Besse, T. J. Lynch et al., “Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 28, no. 18, pp. 3076–3083, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. P. A. Jänne, D. S. Boss, D. R. Camidge et al., “Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors,” Clinical Cancer Research, vol. 17, no. 5, pp. 1131–1139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. C. A. Eberlein, D. Stetson, A. A. Markovets et al., “Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models,” Cancer Research, vol. 75, no. 12, pp. 2489–2500, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. P. A. Jänne, J. Chih-Hsin Yang, D.-W. Kim et al., “AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer,” The New England Journal of Medicine, vol. 372, no. 18, pp. 1689–1699, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. L. V. Sequist, J.-C. Soria, J. W. Goldman et al., “Rociletinib in EGFR-mutated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 372, no. 18, pp. 1700–1709, 2015. View at Publisher · View at Google Scholar
  123. K. S. Thress, C. P. Paweletz, E. Felip et al., “Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M,” Nature Medicine, vol. 21, no. 6, pp. 560–562, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. Z. Zeng, H.-H. Yan, X.-C. Zhang et al., “Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor,” Lung Cancer, vol. 86, no. 2, pp. 219–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. J.-S. Tseng, T.-Y. Yang, K.-C. Chen et al., “Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma,” OncoTargets and Therapy, vol. 7, pp. 799–805, 2014. View at Publisher · View at Google Scholar · View at Scopus
  126. Y. Y. Janjigian, C. G. Azzoli, L. M. Krug et al., “Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib,” Clinical Cancer Research, vol. 17, no. 8, pp. 2521–2527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. Y. Janjigian, E. F. Smit, H. J. M. Groen et al., “Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations,” Cancer Discovery, vol. 4, no. 9, pp. 1036–1045, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. D. W. Wu, T. C. Wu, C. Y. Chen, and H. Lee, “PAK1 is a novel therapeutic target in tyrosine kinase inhibitor-resistant lung adenocarcinoma activated by the PI3K/AKT signaling regardless of EGFR mutation,” Clinical Cancer Research, 2016. View at Google Scholar
  129. J. H. Park, Y. J. Choi, S. Y. Kim et al., “Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer,” Oncotarget, vol. 7, no. 16, pp. 22005–22015, 2016. View at Publisher · View at Google Scholar
  130. K. Suda, H. Mizuuchi, Y. Maehara, and T. Mitsudomi, “Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutationdiversity, ductility, and destiny,” Cancer and Metastasis Reviews, vol. 31, no. 3-4, pp. 807–814, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. M. Del Re, M. Tiseo, P. Bordi et al., “Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  132. S.-H. Park, M.-A. Seong, and H.-Y. Lee, “p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells,” Oncotarget, vol. 7, no. 7, pp. 8184–8199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  133. J. E. Lee, H. S. Park, D. Lee et al., “Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance,” Biochemical and Biophysical Research Communications, vol. 474, no. 1, pp. 154–160, 2016. View at Publisher · View at Google Scholar
  134. J. Y. Li, Y. Ren, Y. Yuan et al., “Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice,” Acta Pharmacologica Sinica, vol. 37, no. 7, pp. 930–940, 2016. View at Publisher · View at Google Scholar
  135. X. Y. Bai, X. Zhang, S. Yang et al., “Blockade of hedgehog signaling synergistically increases sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer cell lines,” PLOS ONE, vol. 11, no. 3, Article ID e0149370, 2016. View at Publisher · View at Google Scholar
  136. S. L. Moores, M. L. Chiu, B. S. Bushey et al., “A novel bispecific antibody targeting EGFR and cMet that is effective against EGFR inhibitor- resistant lung tumors,” Cancer Research, vol. 76, no. 13, pp. 3942–3953, 2016. View at Publisher · View at Google Scholar
  137. Y. Wang, H. Huang, L. Yang, Z. Zhang, and H. Ji, “Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance,” Scientific Reports, vol. 6, Article ID 25468, 2016. View at Publisher · View at Google Scholar
  138. Y. Wu, D.-D. Yu, Y. Hu et al., “Genome-wide profiling of long non-coding RNA expression patterns in the EGFR-TKI resistance of lung adenocarcinoma by microarray,” Oncology Reports, vol. 35, no. 6, pp. 3371–3386, 2016. View at Publisher · View at Google Scholar
  139. S. Park, E. Langley, J.-M. Sun et al., “Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer,” Oncotarget, vol. 6, no. 31, pp. 30929–30938, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. A. G. Sacher, L. W. Le, H. Lara-Guerra et al., “A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  141. Z. Wang, R. Chen, S. Wang et al., “Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC,” PLoS ONE, vol. 9, no. 11, Article ID e110780, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. “First-line crizotinib versus chemotherapy in ALK-positive lung cancer,” The New England Journal of Medicine, vol. 373, no. 16, article 1582, 2015. View at Publisher · View at Google Scholar
  143. Y. L. Choi, M. Soda, Y. Yamashita et al., “EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1734–1739, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. R. C. Doebele, A. B. Pilling, D. L. Aisner et al., “Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer,” Clinical Cancer Research, vol. 18, no. 5, pp. 1472–1482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. T. Sasaki, K. Okuda, W. Zheng et al., “The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers,” Cancer Research, vol. 70, no. 24, pp. 10038–10043, 2010. View at Publisher · View at Google Scholar · View at Scopus
  146. R. Katayama, A. T. Shaw, T. M. Khan et al., “Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers,” Science Translational Medicine, vol. 4, no. 120, pp. 120–ra17, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. N. Yamaguchi, A. R. Lucena-Araujo, S. Nakayama et al., “Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer,” Lung Cancer, vol. 83, no. 1, pp. 37–43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  148. H. Isozaki, E. Ichihara, N. Takigawa et al., “Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases,” Cancer Research, vol. 76, no. 6, pp. 1506–1516, 2016. View at Publisher · View at Google Scholar
  149. A. T. Shaw, D.-W. Kim, R. Mehra et al., “Ceritinib in ALK-rearranged non-small-cell lung cancer,” The New England Journal of Medicine, vol. 370, no. 13, pp. 1189–1197, 2014. View at Publisher · View at Google Scholar
  150. T. Seto, K. Kiura, M. Nishio et al., “CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study,” The Lancet Oncology, vol. 14, no. 7, pp. 590–598, 2013. View at Publisher · View at Google Scholar · View at Scopus
  151. R. J. Nilsson, N. Karachaliou, J. Berenguer et al., “Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer,” Oncotarget, vol. 7, no. 1, pp. 1066–1075, 2016. View at Publisher · View at Google Scholar
  152. C. Iragavarapu, M. Mustafa, A. Akinleye et al., “Novel ALK inhibitors in clinical use and development,” Journal of Hematology and Oncology, vol. 8, no. 1, article 17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  153. L. Li, Y. Wang, T. Peng et al., “Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway,” Oncotarget, 2016. View at Publisher · View at Google Scholar
  154. T. Tani, H. Yasuda, J. Hamamoto et al., “Activation of EGFR bypass signaling by TGFa overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells,” Molecular Cancer Therapeutics, vol. 15, no. 1, pp. 162–171, 2016. View at Publisher · View at Google Scholar · View at Scopus
  155. A. S. Crystal, A. T. Shaw, L. V. Sequist et al., “Patient-derived models of acquired resistance can identify effective drug combinations for cancer,” Science, vol. 346, no. 6216, pp. 1480–1486, 2014. View at Publisher · View at Google Scholar · View at Scopus
  156. F. H. Wilson, C. M. Johannessen, F. Piccioni et al., “A functional landscape of resistance to ALK inhibition in lung cancer,” Cancer Cell, vol. 27, no. 3, pp. 397–408, 2015. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Inoue, H. Toki, J. Matsui et al., “Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency,” Carcinogenesis, vol. 37, no. 5, pp. 452–460, 2016. View at Publisher · View at Google Scholar
  158. Y. Arai, Y. Totoki, H. Takahashi et al., “Mouse model for ROS1-rearranged lung cancer,” PLoS ONE, vol. 8, no. 2, article e56010, 2013. View at Publisher · View at Google Scholar · View at Scopus
  159. M. M. Awad, R. Katayama, M. McTigue et al., “Acquired resistance to crizotinib from a mutation in CD74-ROS1,” The New England Journal of Medicine, vol. 368, no. 25, pp. 2395–2401, 2013. View at Publisher · View at Google Scholar
  160. M. A. Davare, A. Saborowski, C. A. Eide et al., “Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 48, pp. 19519–19524, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. M. Saito, T. Ishigame, K. Tsuta, K. Kumamoto, T. Imai, and T. Kohno, “A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis,” Carcinogenesis, vol. 35, no. 11, pp. 2452–2456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  162. C. W. Kang, K. W. Jang, J. Sohn et al., “Antitumor activity and acquired resistance mechanism of dovitinib (TKI258) in RET-rearranged lung adenocarcinoma,” Molecular Cancer Therapeutics, vol. 14, no. 10, pp. 2238–2248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Zhang, L. Zhang, X. Su et al., “Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models,” Clinical Cancer Research, vol. 18, no. 24, pp. 6658–6667, 2012. View at Publisher · View at Google Scholar · View at Scopus
  164. E. M. Beauchamp, B. A. Woods, A. M. Dulak et al., “Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss,” Molecular Cancer Therapeutics, vol. 13, no. 2, pp. 475–482, 2014. View at Publisher · View at Google Scholar · View at Scopus
  165. J. R. Gomes and M. R. S. Cruz, “Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors,” OncoTargets and Therapy, vol. 8, pp. 1137–1142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  166. C. Voena and R. Chiarle, “Advances in cancer immunology and cancer immunotherapy,” Discovery Medicine, vol. 21, no. 114, pp. 125–133, 2016. View at Google Scholar